KBC Group NV Has $62.56 Million Stake in Cencora, Inc. (NYSE:COR)

KBC Group NV cut its stake in shares of Cencora, Inc. (NYSE:COR) by 16.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 277,923 shares of the company’s stock after selling 53,152 shares during the quarter. KBC Group NV owned approximately 0.14% of Cencora worth $62,555,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new position in shares of Cencora in the first quarter worth approximately $2,183,619,000. JPMorgan Chase & Co. bought a new stake in shares of Cencora in the 1st quarter valued at $1,199,695,000. Boston Partners acquired a new stake in shares of Cencora during the first quarter worth $1,001,269,000. Capital Research Global Investors acquired a new position in Cencora in the first quarter valued at $650,424,000. Finally, Bessemer Group Inc. acquired a new stake in Cencora during the 1st quarter worth about $556,245,000. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. UBS Group upped their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Bank of America reaffirmed a “neutral” rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Evercore ISI raised their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $271.20.

Cencora Price Performance

Cencora stock opened at $249.95 on Thursday. The stock has a market cap of $49.25 billion, a P/E ratio of 33.28, a P/E/G ratio of 1.66 and a beta of 0.44. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company’s 50 day moving average price is $232.38 and its two-hundred day moving average price is $231.00. Cencora, Inc. has a 52 week low of $191.11 and a 52 week high of $251.56.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. Cencora’s dividend payout ratio (DPR) is currently 27.16%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.